Chikungunya vaccine

Last updated

Chikungunya vaccine
Vaccine description
Target Chikungunya virus
Vaccine type Attenuated
Clinical data
Trade names Ixchiq, others
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Intramuscular
ATC code
  • None
Legal status
Legal status

Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus. [7] [9]

Contents

The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site. [14]

The first chikungunya vaccine was approved for medical use in the United States in November 2023. [14] Chikungunya vaccines were also authorized in the European Union in May 2024. [10] [12] [15]

In May 2025, the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention recommended a pause in the use of the chikungunya vaccine (Ixchiq) in people aged 60 years of age and older based on reports of serious neurologic, cardiac, and other adverse events in vaccine recipients. [16] The FDA removed the pause in August 2025. [16] The European Medicines Agency paused the use of the vaccine in people aged 65 years of age and older in May 2025, [17] and resumed its use in July 2025. [18] The UK Medicines and Healthcare products Regulatory Agency paused the use of the vaccine in people aged 65 years of age and older in June 2025. [5] [19]

Medical uses

The chikungunya vaccine is indicated for the prevention of disease caused by chikungunya virus. [6] [8]

History

The safety of the chikungunya vaccine was evaluated in two clinical studies conducted in North America in which about 3,500 participants 18 years of age and older received a dose of the vaccine with one study including about 1,000 participants who received a placebo. [14] The effectiveness of the chikungunya vaccine is based on immune response data from a clinical study conducted in the United States in individuals 18 years of age and older. [14] In this study, the immune response of 266 participants who received the vaccine was compared to the immune response of 96 participants who received placebo. [14] The level of antibody evaluated in study participants was based on a level shown to be protective in non-human primates that had received blood from people who had been vaccinated. [14] Almost all vaccine study participants achieved this antibody level. [14]

The US Food and Drug Administration (FDA) granted the application for the chikungunya vaccine fast track, breakthrough therapy, and priority review designations. [14] The FDA granted approval of Ixchiq to Valneva Austria GmbH. [14] [20] Several additional chikungunya vaccine candidates are under development. [21]

Society and culture

In May 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agencyadopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ixchiq, intended for the prevention of chikungunya disease in adults. [10] The applicant for this medicinal product is Valneva Austria GmbH. [10] [22] Ixchiq was reviewed under EMA's accelerated assessment program. [10] [15] It contains the live attenuated chikungunya virus (CHIKV) Δ5nsP3 strain of the ECSA/IOL genotype. [10] Ixchiq was authorized for medical use in the European Union in June 2024. [10] [11]

In January 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vimkunya (chikungunya vaccine (recombinant, adsorbed)), a vaccine intended for the prevention of chikungunya disease in individuals aged twelve years of age and older. [12] The applicant for this medicinal product is Bavarian Nordic A/S. [12] [23] Vimkunya was authorized for medical use in the European Union in February 2025. [12] [13] In July 2025, the EMA lifted its suspension of the European license for Ixchiq, [24] but in August 2025, the FDA suspended Ixchiq from the United States market, asserting adverse reactions. [25]

References

  1. ↑ "Register Of Innovative Drugs [Updated: 2024-07-04]". Health Canada . 4 July 2024. Retrieved 15 July 2024.
  2. ↑ "Ixchiq Product information". Health Canada . 20 June 2024. Archived from the original on 15 July 2024. Retrieved 15 July 2024.
  3. ↑ "Summary Basis of Decision for Ixchiq". Drug and Health Products Portal. 1 September 2012. Retrieved 17 December 2024.
  4. ↑ "Regulatory Decision Summary for Ixchiq". Drug and Health Products Portal. 20 June 2024. Archived from the original on 7 December 2024. Retrieved 27 December 2024.
  5. 1 2 "iIxchiq Chikungunya vaccine: temporary suspension in people aged 65 years or older". GOV.UK. 18 June 2025. Archived from the original on 24 June 2025. Retrieved 28 July 2025.
  6. 1 2 "Ixchiq- chikungunya vaccine, live-attenuated injection, powder, lyophilized, for solution". DailyMed. 9 November 2023. Retrieved 2 April 2025.
  7. 1 2 "Ixchiq". U.S. Food and Drug Administration. 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  8. 1 2 "Vimkunya- chikungunya vaccine, recombinant injection, suspension". DailyMed. 18 February 2025. Retrieved 2 April 2025.
  9. 1 2 "Vimkunya". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 4 March 2025. Retrieved 3 March 2025.
  10. 1 2 3 4 5 6 7 "Ixchiq EPAR". European Medicines Agency . 30 May 2024. Archived from the original on 1 June 2024. Retrieved 1 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  11. 1 2 "Ixchiq PI". European Medicines Agency . 30 May 2024. Archived from the original on 1 June 2024. Retrieved 2 July 2024.
  12. 1 2 3 4 5 "Vimkunya EPAR". European Medicines Agency . 30 January 2025. Archived from the original on 16 February 2025. Retrieved 16 February 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  13. 1 2 "Vimkunya PI". Union Register of medicinal products. 28 February 2025. Retrieved 4 March 2025.
  14. 1 2 3 4 5 6 7 8 9 "FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus". U.S. Food and Drug Administration (FDA) (Press release). 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  15. 1 2 "First vaccine to protect adults from Chikungunya". European Medicines Agency (Press release). 31 May 2024. Retrieved 1 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  16. 1 2 "FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live)". U.S. Food and Drug Administration (FDA). 7 August 2025. Retrieved 7 August 2025.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  17. ↑ "EMA starts review of Ixchiq (live attenuated chikungunya vaccine)". European Medicines Agency (Press release). 7 May 2025. Archived from the original on 9 July 2025. Retrieved 28 July 2025.
  18. ↑ "Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted". European Medicines Agency (Press release). 11 July 2025. Retrieved 27 July 2025.
  19. ↑ "Chikungunya vaccine in UK travellers: JCVI advice". GOV.UK. 16 July 2025. Retrieved 7 August 2025.
  20. ↑ Malhi S (10 November 2023). "FDA approves first vaccine against mosquito-borne virus chikungunya". The Washington Post . Archived from the original on 11 November 2023. Retrieved 13 November 2023.
  21. ↑ Maure C, Khazhidinov K, Kang H, Auzenbergs M, Moyersoen P, Abbas K, et al. (December 2024). "Chikungunya vaccine development, challenges, and pathway toward public health impact". Vaccine. 42 (26) 126483. doi: 10.1016/j.vaccine.2024.126483 . PMID   39467413.
  22. ↑ "Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27–30 May 2024". European Medicines Agency (Press release). 31 May 2024. Archived from the original on 13 June 2024. Retrieved 13 June 2024.
  23. ↑ "New Chikungunya vaccine for adolescents from 12 and adults". European Medicines Agency (Press release). 31 January 2025. Archived from the original on 16 February 2025. Retrieved 16 February 2025.
  24. ↑ Day D (18 July 2025). "EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review". Pharmafile.
  25. ↑ "Valneva shares tumble after suspension of US chikungunya vaccine licence". Reuters. 25 August 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.